The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Viome and Helomics Partner to Identify Personalized Treatment for Ovarian Cancer Patients
Oncology

Viome and Helomics Partner to Identify Personalized Treatment for Ovarian Cancer Patients

MAR 27, 2019
New Study Identifies Potential Treatment For Higher Rate Of Preterm Birth Among African American Women
Pharma & Human Health

New Study Identifies Potential Treatment For Higher Rate Of Preterm Birth Among African American Women

MAR 27, 2019
Clinical Study Results Demonstrate Benefits of High-Potency, Multi-Strain Probiotic Formulations
Biotics and Supplements

Clinical Study Results Demonstrate Benefits of High-Potency, Multi-Strain Probiotic Formulations

MAR 25, 2019
Intellectual Property Considerations for the Microbiome: Personalized Strategies for a Diverse Space
Editor's Choice

Intellectual Property Considerations for the Microbiome: Personalized Strategies for a Diverse Space

MAR 25, 2019
MTIG Position Statement on FMT Regulations
Pharma & Human Health

MTIG Position Statement on FMT Regulations

MAR 25, 2019
Enterome Announces Research Collaboration with Dana-Farber Cancer Institute Focused on New Microbiome-derived Cancer Immunotherapy
Oncology

Enterome Announces Research Collaboration with Dana-Farber Cancer Institute Focused on New Microbiome-derived Cancer Immunotherapy

MAR 22, 2019
Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
Finance

Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca

MAR 11, 2019
SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials
Clinical & Manufacturing

SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials

MAR 11, 2019
L’Oréal Announces Partnership With uBiome To Advance New Research Into The Skin Microbiome
Finance

L’Oréal Announces Partnership With uBiome To Advance New Research Into The Skin Microbiome

MAR 11, 2019
On Intended Use – the Alpha & Ωmega of Defining Regulatory Status
Pharma & Human Health

On Intended Use – the Alpha & Ωmega of Defining Regulatory Status

MAR 5, 2019
Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close
Editor's Choice

Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close

MAR 5, 2019